Lyell Immunopharma, Inc.
LYELDrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
7dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
LYEL Earnings Report
EPS Est: $-1.94 | FQ end 2026-06
How LYEL's past catalysts played out
rondecabtagene autoleucel
Large B-cell Lymphoma
LYL314
Relapsed Non-Hodgkin Lymphoma
LYL273
Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
rondecabtagene autoleucel | Phase 3 | Large B-cell Lymphoma | - | - |
LYL314 | Phase 2 | Relapsed Non-Hodgkin Lymphoma | - | - |
LYL273 | Phase 2 | Colorectal Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Lyell Immunopharma, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Lyell Immunopharma, Inc.'s (LYEL) pipeline across Phase 3, Phase 2. Its lead program is rondecabtagene autoleucel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lyell Immunopharma, Inc.'s next FDA catalyst?→
Lyell Immunopharma, Inc.'s (LYEL) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track LYEL biotech catalysts?→
Add LYEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lyell Immunopharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.